Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 8/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840017 | 0.99 | PARP1 (0.39) | PARP1PARP2PARP14TLR7ADORA3 | |
| SCHEMBL7488417 | 0.88 | NPY1R (0.36) | PARP1PARP2PARP14TLR7ADORA3 | |
| SCHEMBL6838070 | 0.87 | NPY1R (0.37) | PARP1PARP2PARP14TLR7ADORA3 | |
| SCHEMBL6839979 | 0.83 | ADRB2 (0.35) | TLR7ADORA3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6840155 | 0.83 | SSTR4 (0.38) | PARP14TLR7ADORA3 | |
| SCHEMBL6840039 | 0.82 | ADRB2 (0.36) | TLR7ADORA3KDM4EALDH1A1 | |
| SCHEMBL6838736 | 0.82 | SSTR4 (0.38) | PARP14ADORA3 | |
| SCHEMBL6833824 | 0.81 | KDM4E (0.38) | PARP1KDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL6833699 | 0.80 | ACHE (0.37) | ADORA3 | |
| SCHEMBL6837640 | 0.80 | ADORA3 (0.38) | TLR7ADORA3NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | PARP1 2570/4885PARP2 4197/4885PARP14 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.